Pila Pharma AB (publ) (PILA.ST)
SEK 3.87
(5.16%)
SEK 3.87
(5.16%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.79 Million SEK | 32.21% |
| 2022 | 1.35 Million SEK | -10.42% |
| 2021 | 1.51 Million SEK | -22.2% |
| 2020 | 1.94 Million SEK | 301.72% |
| 2019 | 484.67 Thousand SEK | -41.04% |
| 2018 | 821.97 Thousand SEK | 46.42% |
| 2017 | 561.36 Thousand SEK | -12.93% |
| 2016 | 644.76 Thousand SEK | 162.19% |
| 2015 | 245.91 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.91 Million SEK | 6.58% |
| 2024 Q2 | 1.91 Million SEK | 0.0% |
| 2023 Q4 | 1.79 Million SEK | -42.81% |
| 2023 FY | 1.79 Million SEK | 32.21% |
| 2023 Q1 | 1.34 Million SEK | -1.18% |
| 2023 Q2 | 1.03 Million SEK | -23.12% |
| 2023 Q3 | 3.13 Million SEK | 204.27% |
| 2022 Q2 | 1.12 Million SEK | -24.6% |
| 2022 FY | 1.35 Million SEK | -10.42% |
| 2022 Q1 | 1.49 Million SEK | -1.24% |
| 2022 Q4 | 1.35 Million SEK | 16.78% |
| 2022 Q3 | 1.16 Million SEK | 3.01% |
| 2021 Q1 | 2.12 Million SEK | 9.35% |
| 2021 FY | 1.51 Million SEK | -22.2% |
| 2021 Q4 | 1.51 Million SEK | -12.75% |
| 2021 Q3 | 1.73 Million SEK | -7.9% |
| 2021 Q2 | 1.88 Million SEK | -11.46% |
| 2020 FY | 1.94 Million SEK | 301.72% |
| 2020 Q4 | 1.94 Million SEK | 0.0% |
| 2019 FY | 484.67 Thousand SEK | -41.04% |
| 2018 FY | 821.97 Thousand SEK | 46.42% |
| 2017 FY | 561.36 Thousand SEK | -12.93% |
| 2016 FY | 644.76 Thousand SEK | 162.19% |
| 2015 FY | 245.91 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 98.317% |
| Ziccum AB (publ) | 6.38 Million SEK | 71.916% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | 23.951% |
| BioArctic AB (publ) | 139.5 Million SEK | 98.714% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | 94.815% |
| Mendus AB (publ) | 51.22 Million SEK | 96.498% |
| Genovis AB (publ.) | 98.04 Million SEK | 98.17% |
| Intervacc AB (publ) | 21.68 Million SEK | 91.725% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | 93.283% |
| Active Biotech AB (publ) | 13.4 Million SEK | 86.612% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 98.553% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | 88.869% |
| Aptahem AB (publ) | 8.99 Million SEK | 80.062% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 95.609% |
| Kancera AB (publ) | 17.97 Million SEK | 90.021% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 96.115% |
| Fluicell AB (publ) | 8.91 Million SEK | 79.877% |
| Saniona AB (publ) | 86.08 Million SEK | 97.916% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | 65.219% |
| Biovica International AB (publ) | 34.76 Million SEK | 94.84% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | 84.625% |
| AcouSort AB (publ) | 10.37 Million SEK | 82.713% |
| Xintela AB (publ) | 14.01 Million SEK | 87.199% |
| Abliva AB (publ) | 16.78 Million SEK | 89.309% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 99.164% |
| Karolinska Development AB (publ) | 11.56 Million SEK | 84.493% |
| OncoZenge AB (publ) | 1.69 Million SEK | -5.592% |
| Amniotics AB (publ) | 10.54 Million SEK | 82.99% |
| 2cureX AB (publ) | 2.93 Million SEK | 38.876% |
| CombiGene AB (publ) | 4.15 Million SEK | 56.833% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | 59.467% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 99.885% |
| Camurus AB (publ) | 414.81 Million SEK | 99.568% |
| Corline Biomedical AB | 6.78 Million SEK | 73.575% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 97.076% |
| Isofol Medical AB (publ) | 19.16 Million SEK | 90.639% |
| I-Tech AB | 16.2 Million SEK | 88.929% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 99.849% |
| Cyxone AB (publ) | 4.69 Million SEK | 61.781% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | 86.54% |
| Biosergen AB | 5.08 Million SEK | 64.72% |
| Cantargia AB (publ) | 54.97 Million SEK | 96.736% |
| NextCell Pharma AB | 13.68 Million SEK | 86.895% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 97.503% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | 86.973% |
| Nanologica AB (publ) | 79.32 Million SEK | 97.738% |
| SynAct Pharma AB | 51.83 Million SEK | 96.539% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | 77.431% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | 65.466% |
| LIDDS AB (publ) | 3.75 Million SEK | 52.236% |
| Lipum AB (publ) | 7.53 Million SEK | 76.201% |
| BioInvent International AB (publ) | 90.45 Million SEK | 98.017% |
| Alzinova AB (publ) | 9.33 Million SEK | 80.774% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 99.012% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | 90.3% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | 53.257% |
| Simris Alg AB (publ) | 148.93 Million SEK | 98.795% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 97.477% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 99.628% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | 85.923% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | 75.289% |